Peptides DB
Research-centric peptide and protocol reference hub
Study 32 of 39HGH (Somatropin) literatureThe Journal of clinical endocrinology and metabolism · ObservationalHigh-impact journal2026

Associations of endocrine disrupting chemicals with anogenital distance across infancy.

Increased exposure to certain phthalates during pregnancy may be associated with shorter anogenital distance in female infants at 5 months, indicating a potential impact on reproductive development.

Read at The Journal of clinical endocrinology and metabolismAdd to compare

Where it sits

this study against the rest of the hgh (somatropin) corpus
2
Preclinical
22
Observational · this one
0
Open-label
10
Randomised
5
Reviews

Summary and findings

This study evaluated associations of maternal endocrine disrupting chemicals (EDCs) with infant anogenital distance (AGD) at birth and at 5 months of age. The study included 563 mother-infant pairs and measured 10 phthalates/replacements and nine phenols in urine samples. Findings indicated that increased exposure to phthalates/replacements was associated with shorter AGD in females at 5 months.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Each quartile increase in the phthalate/replacement mixture was associated with -4.13 mm/m shorter AGIShort (95% CI: -7.22, -1.05) in 5-month-old females.2026

Abstract

The authors’ words, as The Journal of clinical endocrinology and metabolism supplied them

<h4>Context</h4>Pregnant women are ubiquitously exposed to endocrine disrupting chemicals (EDCs). Anogenital distance (AGD) is a hormone-dependent marker of reproductive system development.<h4>Objective</h4>We evaluated associations of maternal EDCs with infant AGD at birth and mini-puberty (5 months), and AGD growth across infancy.<h4>Design</h4>Pregnant women enrolled in I-KIDS (Illinois Kids Development Study)-an observational longitudinal study (2013-2019).<h4>Setting</h4>Participants were recruited from two OBGyn clinics in Champaign-Urbana, IL.<h4>Patients or other participants</h4>This study includes 563 mother/infant pairs at birth and 5-months of age.<h4>Intervention(s)/exposure</h4>We measured 10 phthalates/replacements and nine phenols in five pooled first-morning urine samples collected across pregnancy.<h4>Main outcome measures</h4>In newborns and 5-month-olds, we divided short and long AGD measures by body length (termed anogenital index, AGI) and calculated %AGI growth across infancy. We evaluated covariate-adjusted associations of phthalates/replacements or phenols separately (quantile g-computation) or combined (hierarchical Bayesian kernel machine regression), with AGI measures.<h4>Results</h4>Associations of phthalates/replacements with newborn AGI in females and phenols in males were inconsistent. However, in 5-month-old females, each quartile increase in the phthalate/replacement mixture was associated with -4.13 mm/m shorter AGIShort (95% confidence interval (CI): -7.22, -1.05), -3.89 mm/m shorter AGILong (95%CI: -7.55, -0.23), -39.49% less AGIShort growth (95%CI: -62.44, -16.54), and -8.78% less AGILong growth (95%CI: -16.06, -1.51); associations with AGILong growth were strongest at lower mixture quantiles.<h4>Conclusion</h4>AGD in mini-puberty and growth across infancy may reflect EDC-mediated hormonal disruption in utero, particularly in females, supporting the need to investigate these markers as predictors of long-term reproductive health.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the HGH (Somatropin) corpus

BReal-World Adult Height Outcomes in Girls with Central Precocious Puberty Receiving GnRHa Monotherapy or Combined with Growth Hormone: A Cohort Study in China.Advances in therapy · 2026 · GnRHa + rhGH group AHG: 1.72 SDS (1.24, 2.59).HumanD[Prospects and mechanistic insights into the use of recombinant human growth hormone in the treatment of pediatric inflammatory bowel disease].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026reviewAGH-IGF-1 axis and rhGH outcomes in children with GHD, ISS and SGA: a systematic review and meta-analysis.Journal of pediatric endocrinology & metabolism : JPEM · 2026 · n=18642 · Baseline IGF-1 SDS was lowest in GHD (-2.9 ± 1.1) compared with ISS (-1.5 ± 1.2) and SGA (-1.3 ± 1.1; p<0.001).reviewCComparative Effects of Local Denosumab and Recombinant Human Growth Hormone on Periodontal Remodeling in Experimental Periodontitis.Journal of stomatology, oral and maxillofacial surgery · 2026 · n=24 · Facial bone height: 11.97 ± 0.05 mm for DNS vs. 9.96 ± 0.06 mm for rhGH, P = 0.004.AnimalBPrecision medicine in pediatric growth disorders: Integrating clinical phenotype, genetics, IGF-1 biology and artificial intelligence: A systematic scoping review of PubMed-indexed literature (2000-2026).Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2026 · IGF-1/IGFBP-3 M ratio sensitivity 87.5%, specificity 83.0% for GH deficiency.reviewBBuilding the adult growth hormone deficiency data mart: a Real-World model of AI-driven clinical data extraction in a single Italian center.Journal of endocrinological investigation · 2026 · n=210 · 188 validated AGHD patients out of 210 identified.Human